Methylone demonstrates improvement in PTSD symptoms in Phase 2 study
The Brown University Psychopharmacology Update April 30, 2026 DOI: 10.1002/pu.31448 via OpenAlex
Summary
AI-generated from the abstractFour weekly doses of TSND-201 (methylone), an analog of MDMA, produced significantly greater reductions in PTSD symptoms than placebo in a Phase 2 trial. Adverse effects were mostly mild to moderate, and no significant suicidal ideation occurred. Results appeared in JAMA Psychiatry on February 18, 2026.
Study at a glance
| Characteristics | Phase 2 randomized controlled trial Peer reviewed |
|---|---|
| Dose | four weekly doses |
| Duration | Four weekly doses |
| Keywords | Placebo Adverse effect Phase matter Posttraumatic stress Medicine |
| Key finding | TSND-201 significantly reduced PTSD symptoms compared with placebo over four weekly doses. |
Abstract
Four weekly doses of TSND‐201 (methylone), an analog of 3,4 methylenedioxymethamphetamine (MDMA), resulted in significant improvement relative to placebo in reducing symptoms of post‐traumatic stress disorder (PTSD), a Phase 2 study has found. Treatment‐emergent adverse events associated with TSND‐201 were generally mild to moderate in severity, with no significant suicidal ideation. Study results were published online Feb. 18, 2026, in JAMA Psychiatry .